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Abstract
This quality improvement project aimed to identify anesthesia providers’ knowledge of current
and alternative methods to effectively treat perioperative anxiety in the pediatric population.
Background: Pediatric perioperative anxiety is a prominent complication that anesthesia
providers face daily.
Methods: A literature review was conducted utilizing PubMed, Google Scholar, and the
Cochrane database to research the PICO question. A project intervention was provided to both
physician anesthesiologist as well as certified registered nurse anesthetists (CRNAs) that
included a pre-intervention test, an interventional educational module, and a post-intervention
survey. Statistical analysis was completed to assess the outcomes of the educational
intervention.
Results: The majority of participants were able to identify clinical outcomes of high levels of
preoperative anxiety, the most common pharmacological agent being utilized to sedate the
pediatric population, and its negative side effects. Additionally, knowledge of DEX improved
with all providers understanding not only its antianxiety benefits but also its analgesic
properties.
Discussion: Following the educational intervention, anesthesia providers’ knowledge on the
benefits and use of DEX increased. Further research on improved methods of perioperative
anxiety treatment is indicated. Limitations of the study included small sample size, time
restrictions, and impersonal online platform.

Keywords: Pediatrics, Intranasal DEX, Intranasal Midazolam, Oral Midazolam, Agitation,
Sedation, Anxiety
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The Use of Intranasal Dexmedetomidine Compared to Oral Midazolam in the Pediatric
Preoperative Population for Separation Anxiety. An Educational Module
I. Problem Identification
In the pediatric population, patient anxiety and agitation can result in adverse clinical,
behavioral, and psychological complications. Preoperatively, children with high levels of
anxiety can have complications that include increased length of induction, tachycardia,
hypertension, tachypnea, and higher requirements for anesthetic medications.1,2 Additionally,
these patients can develop behavioral problems that include sleep disorders, eating problems, and
separation anxiety from their parent(s).3 Postoperatively, pediatric patients with high levels of
anxiety have an increased risk of emergence delirium as well as chronic postsurgical pain. These
maladaptive behaviors lead to longer hospital stays and poor recovery when compared to
children with lower levels of anxiety.1
Preoperative anxiety and agitation can result from several factors. Determinants
including previous hospitalizations, anxious parents, being an only child, and no premedication
have been shown to be leading factors contributing to preoperative anxiety.4 Additional
causative factors of preoperative anxiety include age, gender, baseline anxiety, and type of
surgery.5 Within the pediatric population, parental anxiety is a contributing factor that directly
correlates with patient anxiety. Parental anxiety can be attributed to factors such as previous
hospitalizations, being the mother or father, occupation, fear of postoperative pain and
situational factors.5 All of these contributing factors should be addressed when caring for the
pediatric population in order to decrease patient anxiety and agitation.
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Background
Given the various negative side effects of perioperative anxiety and agitation, clinicians
have prioritized methods to recognize and ease these conditions in children. Currently,
multimodal approaches are being utilized to help alleviate unease and agitation in the pediatric
population. These methodologies often include pharmacological, nonpharmacological,
behavioral, and psychological approaches.6 Nonpharmacological and behavioral methods
include music therapy, parental presence, play intervention, child life specialist, handheld video
games, and clowns during induction.6 These methods are often well received and can be
beneficial in reducing anxiety in both the patient as well as the parent.
While nonpharmacological and behavioral tactics have been shown to be successful,
many pediatric patients need additional interventions to help alleviate their nerves.
Pharmacological interventions vary and include midazolam, clonidine, ketamine alone or in
combination with midazolam, fentanyl, melatonin, and DEX.4 The most common
pharmacological agent currently being utilized is midazolam. It can be given orally, intranasally,
intravenously, and intramuscularly, and each method of administration has its own advantages
and disadvantages. For example, intranasal administration is quick, easy, and noninvasive;
however, this route of administration of midazolam can cause significant nasal irritation.7,8
While effective in providing adequate sedation and reducing anxiety levels, midazolam has been
shown to cause respiratory depression, can contribute to emergence delirium and cognitive
impairment, and has no analgesic properties.2,7 For these reasons, other agents are now being
studied and utilized in order to provide more effective sedation while decreasing negative side
effects.
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Scope of the Problem
Preoperative anxiety is a common occurrence for anyone undergoing surgery and even
more so in the pediatric population. Anxiety is a feeling of worry, nervousness, or unease about
something with an uncertain outcome.9 In the pediatric population, anxiety may manifest as
trembling, being silent or crying, or being restless. The majority of this patient population does
not have the bandwidth to communicate their fears or feelings with staff or with their parents.
Pediatric patients often feel anxious due to the lack of knowledge and understanding of the
process as well as the limited control of the environment. Adding to the stress of situation is the
anticipation of being separated from their parent or caregiver. This preoperative anxiety is
associated with both physical and psychological consequences.
Almost three fourths of all pediatric patients showcase preoperative anxiety, and just as
many will shows sign of postoperative agitation.5,10 Despite their high incidence, these topics
remain understudied. Post-anesthesia agitation has been linked to increased levels of
preoperative anxiety.9 Despite the multimodal approaches that are currently being utilized, there
continues to be a high incidence of anxiety in the pediatric population. New and alternative
approaches to reduce perioperative anxiety need to be studied to facilitate enhanced recovery and
decreased postoperative complications in the patient population.
Consequences of the Problem
Undergoing surgery can be a very stressful event for any individual and particularly so
for the pediatric population. These patients may not always comprehend what is happening, are
placed in a foreign environment, and are separated from their parents only to have masked
strangers coming towards them from all angles. This preoperative anxiety can lead to
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hemodynamic instability, increased postoperative pain, metabolic side effects, and emergence
delerium.11 Increased levels of anxiety and agitation can also lead to increased recovery times
and increased incidence of postoperative surgical pain.1,12 Effective multimodal approaches to
mitigate anxiety in this patient population can be beneficial not only to the patient, but also to
medical care givers and parents.
Knowledge Gaps
There are many approaches being utilized to help mitigate preoperative anxiety and
agitation in the pediatric population. Each of these modalities have a variety of advantages and
disadvantages. Additionally, the degree to which one approach works over another has not been
consistently documented. Furthermore, there are a variety of pharmacological agents that are
being utilized as anxiolytics. Each of these agents can be administered by various routes. There
are a handful of medications that have been explored and are currently being used in the
pediatric population. There remains no clear solution on which medication and which
administration route can be administered fast, is effective, and will reduce preoperative anxiety
with minimal side effects.
Proposal Solution
DEX is a selective alpha 2 receptor agonist that has a variety of properties, including
sedation, antianxiety, hypnotics and pain relief.3 The sedative properties of DEX are achieved
from its effects on the locus ceruleus that result in a state of consciousness that closely mimics
natural sleep.13 This sleep-like resemblance allows for an easy arousal from sedation. There are
numerous publications outlining the benefits and effective use of DEX; however, the
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effectiveness of intranasal DEX compared to other agents have been not been readily
documented.
Rationale and Objective
Currently, midazolam is the most utilized pharmacological agent to abate preoperative
anxiety. Midazolam, while effective, also has a number of unwanted side effects including,
cognitive impairment, respiratory depression, and postoperative behavioral changes.7 DEX has
been shown to be a useful and safe alternative. DEX most closely emulates sleep and does not
have the depressive respiratory effects that can occur with benzodiazepines. For these reasons,
further investigation into the intranasal effectiveness of DEX compared to midazolam in
reducing preoperative anxiety in the pediatric population is warranted.
II. Literature Review
Eligibility Criteria
The studies evaluated for the literature review included those that would help to garner
information on the knowledge gaps outlined above. Studies included in the search were those
studies that were published within the last 7 years and those that were in English or translated
into English and had full text availability. Exclusion criteria included those studies in which the
patient population was exclusively over the age of 8. Additionally, the studies collected had to
evaluate the effectiveness of intranasal DEX, intranasal or oral midazolam, or a comparison of
both. The collected studies focused on both the effects and side effects of these medications and
measured sedation levels and effects on preoperative anxiety.
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Information Sources
The databases used to collect studies for the literature review included PubMed, Google
Scholar, and the Cochrane database. The studies found on all databases were cross referenced to
ensure that all available relevant studies were included in the review. Figure 1 below outlines
the studies that were eliminated from the search and those that were included based on relevance.
Figure 1. Summary of Literature Search Process

Include
d

Screening

Identification

Identification of studies via databases and registers

Records
identified
from
PubMed and Google Scholar:
Databases (n = 478)

Records
removed
before
screening:
Duplicate records removed
(n = 52)
Records marked as ineligible
by automation tools (n = 200)
Records removed for other
reasons (n = 194)

Records screened
(n = 32)

Records excluded (Not RCT)
(n = 16)

Reports sought for retrieval
(n = 16)

Reports not retrieved – unable
to obtain full report
(n = 6)

Reports assessed for eligibility
(n = 10)

Reports excluded –
Age > 8 (n = 4)

Studies included in review
(n = 6)

Search Strategy
The keyword search terms included in the review were expanded to include: (Pediatric
OR Child* OR Youth) AND (Intranasal DEX OR Intranasal Precedex) AND (Intranasal
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Midazolam OR Intranasal Versed OR Oral Midazolam) AND (Agitation OR Irritation OR
Delirium) OR (Sedation OR Comfort OR Relaxation). The initial search produced a total of 478
articles. PubMed produced 219 results, and Google Scholar produced 259 articles. In order to
ensure the most current studies were included, the search criterion included those studies
published no more than 6 years ago. This generated 112 articles in PubMed and 134 articles in
Google Scholar. The remaining articles were compared for duplicates and relevance and
included only if they had full text. Titles were excluded if they did not include either intranasal
DEX or midazolam along with pediatric and sedation or agitation. Additionally, articles were
excluded if they had words such as adult, intramuscular, intravenous, teenagers, or any
medication that was not DEX or Midazolam.
This yielded a total of 32 articles, and these remaining articles were analyzed by their
abstracts. Of the 32 articles, 16 remained relevant to the study purpose and full texts were
reviewed. Articles were resigned if there was not a direct study including intranasal DEX or
midazolam. Additionally, articles that compared populations other than the younger pediatric
population (aged 2-8) were eliminated. The final search resulted in 6 high quality articles that
will be summarized.
Medical Subject Headings (MeSH)
Based on the PICO question, the search criterion included the following keywords:
Pediatrics, Intranasal DEX, Intranasal Midazolam, Oral Midazolam, Anxiety, Agitation, and
Sedation.
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Figure 2. MeSH Terminology

Pediatric OR
Children

Anxiety,
Agitation,
OR
Sedation

AND

AND

Intranasal
DEX
AND

AND

Intranasal
Midazolam OR Oral
Midazolam

Study Characteristics
Six studies were chosen for this literature review, and 2 main concepts were evaluated.
The first concept was the use and effectiveness of intranasal DEX as an alternative
premedication sedative to reduce anxiety in the pediatric population. The second concept was to
assess post-anesthesia agitation and pain levels in children that received intranasal DEX versus
intranasal or oral midazolam. The first study is a prospective observational study that analyzed
the effectiveness and safety of the use of intranasal DEX in the preoperative period. Four of the
articles were direct Level 1 clinical research studies that compared the effectiveness and use of
intranasal DEX to intranasal or oral midazolam in the pediatric population. The studies included
the pediatric population undergoing a variety of studies including, but not limited to strabismus
studies, laceration repair, MRI studies, and cardiac catherization. The last study was a
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systematic review to identify the effects of oral midazolam as a premedication in children.14 As
an exception, 1 study that was more than 6 years old was included in the study for its relevance
to the concepts of the paper.
Results
Six studies ended up meeting the eligibility criteria for the literature review. Two
systematic reviews were included 1- analyzing DEX and the other outlining the benefits and
statistical data of midazolam. The other 4 studies were small scale randomized control studies
that looked at the benefits, different application methods and different dosing of either DEX or
midazolam. These studies included sample sizes ranging from 90 to 400 and included pediatric
facilities from across the country.
Currently, there are many approaches being utilized to help mitigate preoperative anxiety
in the pediatric population. Each of these modalities have a variety of advantages and
disadvantages. The most common route in the pediatric population for administering
premedication is oral; however, this route has low bioavailability.14 Rectal administration can be
painful, and children can expel the medication, leaving this option inappropriate for older
children. Intramuscular approach is invasive, painful, and difficult to administer on young
children. The most effective route of premedication for pediatric patients is transmucosal—this
includes intranasal. This route is effective due to its high vascularization of mucosa and ability
to circumvent first-pass metabolism.14
Additionally, there are a variety of pharmacological agents that are being utilized as
anxiolytics. Each of these agents can be administered by various routes. There are a handful of
medications that have been explored and are currently being used in the pediatric population.
Currently, midazolam is the most utilized medication for premedication for the pediatric
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population; however, it can cause significant respiratory depression in this age group. Intranasal
DEX is beginning to be utilized more in this population with positive results. Intranasal DEX
has a slower onset of action when compared to intranasal DEX;8,11 however, it has superior
sedative effects with parental separation and onset of induction and decreased levels of
postoperative nausea and vomiting, pain and agitation. Additionally, the intranasal method of
administration did not have the irritating effects that intranasal midazolam has been shown to
have.7,8 Lastly, although DEX has been shown to decreased levels of HR and BP in patients,
these decreases have not been shown significantly enough to need rescue medication.14
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Author(s)

Behrle et al.,
(2017)

Li et al.,
(2016)

Lin et al,,
(2016)

Purpose

To evaluate
the use of
intranasal
DEX as a
sedative in the
pediatric
population

To compare
the
effectiveness
of two
different
administration
methods of
intranasal
DEX

To evaluate
the effects of
premedication
with intranasal
DEX on
inhalation
induction and
postoperative
emergence in

Methodology/
Research
Design
Nonexperimental
Observation
study,
Level II

Randomized
Control Trial,
Level 1

Randomized
Control Trial,
Level 1

Intervention(s)/
Measures
Patients were given 3
mcg/kg of intranasal
DEX 40 mins prior to a
scheduled procedure.

In the pediatric
population, two
different methods of
administering intranasal
DEX were compared.
One group recieved 3
mcg per kg of DEX via
and atmoizer and
another group received
3 mcg per kg of DEX
via drops from a syringe

The study aims to test
whether a single dose of
intranasal DEX is
effective in reducing
preoperative anxiety
and emergence
agitation.

Sampling/Setting

109 patients were included in
the study and evaluated based
on the 5-point University of
Michigan Sedation Scale.
Patients included in the study
were those ranging in age from
6 months to 18 years, ASA
levels of I or II, that were
undergoing noninvasive
procedures (ie., radiologic
imaging, echocardiography,
electrocephalography, and
auditory brainstem response)
279 children aged 0-3 were
evaluated in the study.
Children with a known allergy
of DEX, renal or hepatic
dysfunction, nasal discharge,
and learning difficulties were
excluded from the sample size.
Blind registered nurses and
anesthesia providers
administered the medication
and rated behavior, movement,
and sedation scores.
Patients were randomized into
1 of 3 groups. The first group,
D1 (1 mcg/kg of intranasal
DEX), D2 (2 mcg/kg of
intranasal DEX), and Group C
(intranasal saline).
Each group had a total of 30
participants.

Primary Results

Relevant Conclusions

DEX is a safe sedative that
offers sedation, anxiolytic
and analgesic properties.
DEX causes no respiratory
depression and has only
minor hemodynamic
effects.

Intranasal DEX is a safe
and effective medication to
utilize prior to having to
obtain intravenous
catheters.

These patients did have
increased sleep times.

There was no significant
difference in onset of
sedation, behavior and
movement scores, or
UMSS ratings between the
two groups.

Intranasal DEX
administered via atomizer
and drops from a syringe
are both effective routes of
administration. Successful
sedation levels can be
achieved with both.

There were no differences
in vitals.

The participants in groups
D1 and D2 has significantly
lower mask induction
scores and emergence
delirium scores. The total
time spent recovering in
PACU was comparable
among all three groups.

Intranasal DEX with either
a 1 mcg/kg or 2 mcg/kg
dose can reduce the
resistance to mask
induction and decrease the
incidence of postoperative
emergence agitation.
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the pediatric
population

Jun et al.,
(2017)

Cote et al.,
(2002)

To identify the
effects of
intranasal
DEX as a
premedication
in children

To compare 3
doses of a
commercially
prepared oral
midazolam
use in the
pediatric
population

Systematic
Literature
Review
Level 1

Randomized
Control Trial,
Level 1

Literature review
conducted using
EMBASE,
MEDLINE,Ovid
MEDLINE Daily and
Cochrane Controlled
Trials Register, and
Cochrane Database of
Systematic Reviews.
In addition, Web of
Science, Google
Scholar, and KoreaMed
databases were utilized
to retrieve relevant
studies.

This study aims to look
at what dose of oral
midazolam would be
most effective for use as
a pre-sedative in the
pediatric population.

Exclusion factors included
known adverse reactions to
DEX, neurological illness,
developmental delay, parental
refusal, or moderate upper tract
infection.
For the primary study,
inclusion criteria were as
follows: (a) Literature type:
randomized-controlled trials in
all published international
journals without language
restriction; (b) Subjects:
children undergoing
premedication treatment before
surgery; (c) Interventions:
studies evaluating the efficacy
and safety of intranasal DEX
premedication; (d) Outcomes:
the primary outcomes were
sedation at separation from
patients, sedation at anesthesia.

A total of 405 patients from
nine participating centers were
enrolled in the study. The
children were stratified by age
into three groups: 6 months to
less than 2 years, 2 to less than
6 years, and 6 to 16 years old.
Within these groups, the
children were divided further
into three groups based on
dosing – 0.25 mg/kg, 0.5
mg/kgm and 1 mg/kg.
Exclusion criteria included
seizure disorders,

Lastly, clinically
significant decreases in
heart rate that required
interventions were not
observed in any of the 3
groups.
Search of intranasal DEX
resulted in 13 studies. Six
of these studied compared
intranasal DEX to
intranasal midazolam.
Comparison of the studies
showed that intranasal
DEX resulted in more
sedation at parental
separation, less need for
rescue medications,
decreased incidence of
postoperative nausea and
vomiting, and decrease
nasal irritation when
compared to other
premedication regimes.
In all groups and across all
ages, sedation levels and
onset as well as anxiety levels
and onset times were
recorded.
Baseline anxiety levels were
highest among the youngest
age group; however,
successful sedation and
decreased anxiety was
comparable among all groups
and ages.

Intranasal DEX is a safe
and effective alternative for
premedication in children
undergoing surgery.

Doses as small as 0.25
kg/mg of oral midazolam
can be effective in
mitigating pre-procedure
anxiety and as a sedative in
the pediatric population.
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gastrointestinal disorders, and
any medical condition that
could compromise the safety of
the patient.

Manso et al.
(2019)

To determine
the efficacy of
oral
midazolam for
sedation in the
pediatric
population

Systematic
Literature
Review
Level 1

The study was
conducted to research
the effectiveness of oral
midazolam in the
pediatric population.
The systemic review
was conducted using
PubMed and Science
Direct. Any study
conducted from January
1998 to March 2016
that were written in
English and contained
the search terms
“midazolam and
sedation and child”
were evaluated.

Only randomized studies that
used midazolam as a sole
medication were included in
the review. Additionally, only
the studies that were included
had to include evaluation
scales that measured sedation
levels related to minimal or
moderate sedation.
Studies that were conducted as
comparisons to other sedatives
were not included.
Observed vital signs and
reported adverse effects were
outlined.

Onset of sedation was longer
in the group that received the
smallest dose.
Additionally, none of the
patients demonstrated any
significant drop in saturations
before induction.
A total of 25 articles were
selected for the systematic
review. In total, 1610
patients aged 4 months to
18 years were evaluated
and given a dose ranging
from 0.25 to 1.5 mg/kg of
oral midazolam. In
comparison, 138 of the
participants were treated
with placebo.

Overall, oral midazolam is
an effective medication in
providing satisfactory
sedation levels in the
pediatric population.
Incidence of adverse
effects, including
paradoxical reactions and
respiratory events were
seen in with high doses.

DEXMEDETOMIDINE COMPARED TO MIDAZOLAM FOR SEPERATION ANXIETY
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Summary of Evidence
In the first study reviewed written by Behrle et al. (2017), the authors researched the use
of intranasal DEX as a form of sedation in the pediatric population. Patients were recruited into
the study based on age (6 months to 18 years), ASA levels (I or II), and procedure (non-invasive
radiologic imaging, echocardiogram, electrocephalography, and auditory brainstem). Qualifying
patients were administered 3 mcg/kg of intranasal DEX 40 mins prior to the start of the
procedure. Registered nurses documented the patient’s sedation level based a 5- point University
of Michigan sedation scale, as well as vitals, observed interventions, and length of recovery.
Observed interventions included airway events, cardiovascular events, gastrointestinal events,
and patient tolerance.13
The 109 patients that were given intranasal DEX were compared to 690 subjects that
underwent similar procedures but did not receive DEX and were given either midazolam or
propofol instead. Overall, 92% of the patients that received intranasal DEX were successfully
sedated. There were no clinically significant differences in adverse observed events or
interventions in the group of patients that received DEX compared to the non-DEX group. It
was noted that the group that received DEX did have longer sleep times.

While the effectiveness of DEX as a sedative has been documented, the optimal route of
administration in the pediatric population has not been established. In a study completed by Li et
al. (2016), the authors explore the difference in successfully administrating intranasal DEX via
atomizer versus drops from a syringe. The study consisted of a total of 279 children aged 1-3.
Children were randomly assigned to one of two groups, and each received a dose of 3 mcg per
kg. Behavior and movement scores were collected as well as sedation scores based on the
University of Michigan Sedation Score (UMSS). There were no statistically significant

DEXMEDETOMIDINE COMPARED TO MIDAZOLAM FOR SEPERATION ANXIETY
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differences in behavior, movement, or UMSS scores between the two groups. Additionally,
sedation onset times were similar between the two groups, and there were no episodes of oxygen
desaturation or respiratory depression.3

In a study conducted by Lin et al. (2016), the authors evaluate the effectiveness of
intranasal DEX on pediatric patients undergoing cataract surgery. The study aims to prove that a
single dose of intranasal DEX could not only reduce preoperative anxiety but also play a role in
minimizing postoperative emergence agitation. The study included patients ranging from age 1
to 8 that were scheduled for cataract surgery. A total of 98 children were included in the study.
All participants were classified as American Society of Anesthesiologist (ASA) levels of I or II.
Exclusion criteria for the study included those that were allergic to DEX, had neurological or
developmental delays, had a previous or current upper respiratory infection, or parental refusal.
The children were grouped into 1 of 3 groups – Group D1 were given an intranasal DEX dose of
1 mcg/kg, Group D2 were given 2 mcg/kg and Group C were given normal saline.

After administration of medication or normal saline, patients were induced for the
procedure using 8% sevoflurane via a facemask. Cooperation and successful sedation scores
were based on a scale that measured whether the participants were: 1 = calm, cooperative, 2 =
moderate fear of the mask, 3 = combative and crying.15 After the procedure, patients were
evaluated in the PACU every 5 minutes for postoperative agitation. Overall, the groups that
received intranasal DEX were successfully sedated at the time of induction. Induction scores
were highest among the group that received intranasal normal saline. Postoperative agitation
scores were evaluated when using the Pediatric Anesthesia Emergence Delirium (PAED) and a
score of 10 or higher was regarded as postoperative agitation. Treatment with intranasal DEX
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(both doses) significantly decreased postoperative agitation scores when compared to the control
group. Length of stay in the PACU was similar across all groups, and none of the groups
showed significant reductions in vital signs. The study provided evidence that intranasal DEX
cause be successfully and safely used as a pre-sedation as well as a modality to reduce
postoperative agitation.

Included in this review is a meta-analysis completed by Jun et al. (2017) regarding prior
studies conducted to evaluate the use of intranasal DEX in the pediatric patient population. The
analysis included 13 studies and a total of 1168 participants. All of the studies included in the
analysis compared intranasal DEX to an alternative sedative. Many of the articles compared
intranasal midazolam, while a few compared oral midazolam, intranasal ketamine, intranasal
clonidine, and intranasal saline. The analysis revealed that intranasal DEX used as a
premedication in the pediatric population achieved excellent sedation levels at parental
separation, no significant nasal irritation, decreased levels of postoperative nausea and vomiting,
and postoperative alangsesia.14

In the pediatric population, the most commonly prescribed anesthetic medication is oral
midazolam.16 Historically, midazolam has been very successful as a sedative and anxiolytic.
The authors of a study conducted by Cote et al. (2002) aimed to seek the efficacy, safety, and
taste acceptability of three different doses of oral midazolam. The study was conducted across 9
children’s hospitals around the nation and included a total of slightly over 400 patients. The
patients included in the study were aged 6 months to 16 years. All patients were ASA levels I ,
II or III; however, exclusions were made if the participant had seizure disorders, gastrointestinal
disorders, or any condition that would compromise the safety of the patient.
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After administration of three different doses of 0.25 mg/kg, 0.5 mg/kg and 1.0 mg/kg, up
to a maximum of 20 mg, patients were evaluated on several measures. Vitals were collected
before administration and regularly there after until discharge. Sedation was assessed on a 5point scale while anxiety, cooperation, and taste acceptability were assessed on a 4-point scale.
Patients were broken into three age groups: 6 months to less than 2 years, 2 years to less than 6
years, and 6 years to 16 years. Each of these age groups were further divided into one of the
three dosing groups.

Patients in the youngest group had the highest level of base line anxiety.

The

percentage of patients that were successfully sedated after ten minutes of administration of
medication was similar across all groups with 91% of all patients reaching successful sedation
between 10-20 minutes. 16 Again, the youngest group of participants had significantly more
unsatisfactory sedation scores when compared to the other groups. This can possibly be
attributed to the fact that this age group was more likely to grimace, express verbal disinterest, or
reject the medication all together. The onset and level of anxiolysis was positively associated
with the dose of medication. Cooperation at separation from parents was similar between all
groups; however, the percentage of patients that showed cooperation with face masks was
decreased. In addition to sedation and anxiety levels, adverse events were recorded at three
different times. It was noted that the percentage of patients that received 1.0 mg/kg of
midazolam had a higher incidence of adverse events. Overall, the data shows that oral
midazolam can be successfully used to provide effective sedation and reduce anxiety in the
pediatric population.
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A systematic review of the effectiveness of oral midazolam was also included in this
literature review. The review was conducted in 2018 by Manzo et al. and included published
studies from January 1988 to March 2016. The studies included in the review were those that
were randomized studies that assessed the effectiveness of oral midazolam as a sole medication
and evaluated levels of sedation. A total of 25 articles and over 1600 participants were included
in the review. Several studies included in the review also included information regarding
comparative medications also used for sedation in this patient population. The participants of the
study ranged in age from 4 months to 18 years old and the dosing range was between 0.25 mg/kg
up to 1.5 mg/kg with the most common dose of 0.5 mg/kg being utilized. There is also data
collected on 138 patients that were treated with a placebo. Evaluation of effectiveness,
effectiveness in different context situations, comparisons of other sedatives and placebos,
comparisons of doses, comparisons of different age ranges, and safety were among the points
evaluated in the review.

Overall, oral midazolam is an effective medication that can provide satisfactory sedation
levels in the pediatric population. Additionally, oral midazolam was shown to provide anxiolytic
properties in this patient population. The oral form of the medication is comparable with its
alternative competitors. Several different dosages were evaluated in a few studies and incidences
of adverse effects, including paradoxical reactions and respiratory events, were mostly seen with
increasing doses.
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Conclusion
The pediatric population is a challenging subset of patients for anesthesia providers.
They can have increased levels of anxiety not only from the procedure but also from parental
separation, fear of the unknown, being placed in foreign locations, and being surrounded by
strangers. Currently, midazolam is being utilized as a pre-medication to mitigate anxiety level in
this patient population; however, it can cause nasal irritation and respiratory depression. DEX is
an alternative that is being introduced as an alternative to midazolam. Studies have shown that
DEX is a safe alternative that has increased success in preoperative sedation levels including
separation anxiety and has been shown to result in decreased postoperative nausea, vomiting,
pain, and agitation.
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III. Purpose and PICO Clinical Questions
Primary DNP Project Goal
Current and common practice in many pediatric facilities includes the use of midazolam
for moderate sedation. Midazolam has been shown to be effective in preventing stress and
anxiety that comes from parental separation, fear, pain, and the presence of strangers in an
unfamiliar environment.17 This short acting benzodiazepam has been shown to offer not only
sedative effects, but also been shown to offer anxiolytic and hypnotic properties.17 As with all
medications, midazolam comes with the possibility of adverse effects, including respiratory
depression, nausea and vomiting, and paradoxical reactions. Ongoing research and development
of new medications aim to provide the most effective sedation with minimal side effects. DEX
is an alternative medication that is being considered as a sedative and to reduce anxiety among
the pediatric population. The objective of researching alternative medications is to provide the
most appropriate and effective anesthetic care while minimizing adverse effects to enhance
patient satisfaction.
PICO Clinical Question
In the pediatric population (2-8 years old) (P), how does intranasal dexmedetomidine (I)
compare to oral midazolam (C) in providing sedation and reducing separation anxiety (O)?
Population (P): Pediatric age ranging from 2-8 years
Intervention (I): Intranasal Dexmedetomidine
Comparison (C): Oral Midazolam
Outcomes (O): Agitation and sedation levels
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IV. Conceptual Underpinning and Theoretical Framework
SMART Goals and Outcomes
Development of goals and intents were guided by the acronym SMART. These details
include objectives that are specific, measurable, achievable, realistic, and timely and measure
significance and quality.18
Specific
Anesthesia providers administering sedation to the pediatric population will have a clear
understanding of the pros and cons of alternative medications. This will include dosing
information as well as route of administration. The effectiveness and use of safe alternative
sedation medication will be analyzed through the analysis of a questionnaire.
Measurable
The questionnaire measured knowledge pre and post an educational intervention. Results
evaluated current practice regarding drugs, doses, and methods of administration with alternative
medications and methods. All medical personnel, including but not limited to anesthesiologist,
certified registered nurse anesthetist and student registered nurse anesthetist were involved in the
educational intervention.
Achievable
Anesthesia providers were educated on the incidence of anxiety in the pediatric
population. Additionally, providers learned about current practice being utilized and alternative
medications that can help decrease preoperative anxiety in this patient population.

DEXMEDETOMIDINE COMPARED TO MIDAZOLAM FOR SEPERATION ANXIETY

27

Realistic
Educational teaching was provided via an educational link to a PowerPoint presentation
with video. For ease and convivence, access to educational modules as well as pre and post
questionnaires will be provided in electronic form.
Time Based
The educational module as well as pre and post education questionnaire was available for
a 3-week period. During this time, exposed health care personnel were asked to complete the
educational module as well as the pre and post education questionnaire within a weeklong
period. This will allow for evaluation on provider knowledge prior to and after the educational
module.
Program Structure/SWOT Analysis
The development and implementation of the educational module requires a collaborative
effort. In order to ensure that the educational program has the potential for sustainability,
multidisciplinary teams and organizational cooperation is imperative.18 Additionally,
ascertaining opportunities for change, highlighting the value of the project, and identifying the
significance of the project to the appropriate stakeholders will ensure success of its
implementation. A strength, weakness, opportunity, and threat (SWOT) analysis assessment
tool was utilized to anticipate any barriers that may be encountered during the development and
implementation of the project.
As a patient undergoes surgery, they encounter a multidisciplinary group of individuals
all of whom have an impact in their care. Everyone from the admitting nurse and primary
physician to the anesthesia provider and PACU nurse are involved in ensuring that patient has
the best outcome possible. The first step of the project was to identify the expert caregivers that
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have an impact in developing and implementing positive change through education. Next,
identification of individuals that advocated for the safe and effective administration of alternative
sedation medications were targeted. These individuals were asked to complete a pre-education
questionnaire to assess baseline knowledge of current and alternative forms of sedation in the
pediatric population. Educational courses were then provided through a digital platform. Once
completed, a post-education questionnaire was used to analyze and evaluate effectiveness of
teachings.
Strengths
Anesthesia providers work diligently to provide effective anesthesia to their patients
while ensuring their hemodynamic safety. In the pediatric population, mitigating anxiety is of
utmost importance as uncontrolled anxiety can cause a variety of emotional, psychiatric and
physical problems.19 Administering adequate care for their patients while ensuring their safety is
the primary goal for anesthesia providers. While current practices may be effective, they do not
come without drawbacks. Developing and researching new and comparable ways to effectively
sedate patients while decreasing adverse effects not only benefits the patients, but also allows for
patient and provider satisfaction.
Anesthesiologists should consider how the pediatric population experiences perioperative
care to improve practice and outcomes. In the pediatric population, pain and anxiety, along with
thirst are among the most common complaints.20 Therefore, the purpose of this project was to
educate the multidisciplinary team of providers responsible for the care of the pediatric
population on new and alternative forms of reducing anxiety. Developing a perioperative plan
that ensured minimal anxiety while addressing the downfalls of current practice ensures best
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practice. In the ever-changing field of health care, it is important to keep continued exposure to
new and meaningful ways to care for patients.
Weaknesses
Implementation of evidenced-based ideas into practice takes a considerable amount of
planning, discipline, collaboration, and time. Many barriers can prevent even the best of plans
from being executed. Internal traits that could be harmful to a program attributes to the plan’s
weaknesses.18 Additionally, several barriers contribute to the effective execution of an
educational program or plan. Attributes such as culture, communication processes, external
requirements, staff commitment, supportive components, and safety and legal issues can
contribute to barriers to execution.21 To mitigate the number of weaknesses that a project faces,
it is important to identify barriers, be specific and selective in implementing interventions, and
engaging end users.22
Several factors were identified as weaknesses for our organization. Among them were
provider preference, ineffective communication, and lack of time. Anesthesia is an art that can
be administered several different ways by several different providers. One provider may prefer
to medicate all pediatric patients only with oral medications, while other may feel the intranasal
route is best. The lack of consistency in provider preference will make it difficult to collaborate
with all healthcare providers to implement a new medication and an alternate route of
administration. Additionally, ineffective communication may result in inaccurate information
being distributed among providers. Collaborative efforts must be taken to ensure that all end
user individuals receive accurate and current information. Lastly, lack of time and resources to
implement the educational program to an already time-crunched staff may be difficult.
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Opportunities
Every year, the pediatric population undergoes millions of procedures involving
anesthesia. In high-income countries, such as the United States, 1 in 7 children undergo at least
on procedure requiring anesthesia by the age of 4.23 One of the main goals for most medical
facilities is to provide quality healthcare to the people they serve. The goals of perioperative
anesthesia in the pediatric population consists of safe and effective care for both the patient and
the parent. To achieve this, health care providers must stay abreast with new and developing
research in their area of expertise. Anesthesia and its application have evolved tremendously
since its beginning and continues to grow on a day-to-day basis.
Providing educational models to appropriate health care providers allows them to stay
knowledgeable to current and new practice. As medications, methodologies, and models evolve,
so must considerations for anesthesia providers. The educational model will allow providers to
evaluate if using alternative medications, modes of administration or doses will provide better
anesthesia for their patients. Providing the most effective sedation for the pediatric population
allows for decreased length of induction, more stable vitals, and decreased requirements for
anesthetic medications.1,2
Threats and Organizational Factors
In order for a planned project to be successful, it is important to evaluate the potential
risks and barriers that may hinder its successful execution.18 Threats that the education module
may face include lack of time, ineffective communication, and downfalls of online teaching.
During a typical day of a health care worker, time is limited, especially in the operating room
environment. In most cases, there is little time for staff to commit to additional learning. Staff
commitment influenced by the staff’s attitude regarding the proposed intervention can impact the
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implementation process.21 Additionally, communication regarding the purpose of the project is
essential as confusion or disregard of the intervention process can have a negative impact on the
implementation.
To facilitate the ease of implementation of the education module, it can be offered online
so that busy health care workers can complete it when the time is convenient. However, this
method of implementation comes with its own set of threats. Factors that impact online learning
include interaction and collaboration between learner and facilitator, learner motivation and
technology interface.24 In the online platform, collaboration with multiple administrative groups
must occur to effectively implement the educational module.
Conceptual Underpinning and Theoretical Framework of the Project
Designing an intervention for individual-level change includes identifying barriers,
selecting intervention components, using theory, and engaging end users.22 For this educational
module, self-efficacy will be utilized as the theoretical framework. Self-efficacy can be
described as an individual’s judgment of their capabilities to organize and execute courses of
action. These beliefs provide the foundation for human motivation, well-being, and personal
accomplishment.25 Active learning allows in individual to play an active role in their
educational and growth process.
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V. Methodology
Setting and Participants
The study took place in a level one trauma center in Broward County, Florida that offers
quality care to patients of all ages including the pediatric population. The development and
implementation of the educational module will require a collaborative effort. In order to ensure
that the educational program has the potential for sustainability, multidisciplinary teams and
organizational cooperation are imperative.18 Additionally, ascertaining opportunities for change,
highlighting the value of the project, and identifying the significance of the project to the
appropriate stakeholders ensured success of its implementation. The study participants are
certified registered nurse anesthetists (CRNAs) and anesthesiologists working closely with the
pediatric population. The aim of the study is to target CRNAs and anesthesiologists that work
extensively in the pediatric sedation setting.
Description of Approach and Project Procedures
When a patient undergoes surgery, they encounter a multidisciplinary group of
individuals all of whom have an impact in their care. Everyone from the primary physician to
the anesthesia provider are involved in ensuring that patient has the best outcome possible. The
first step of the project was to identify the expert caregivers that have an impact in developing
and implementing positive change through education. Next, identification of individuals that
will advocate for the safe and effective administration of alternative sedation and antianxiolytic
medications were targeted. These CRNAs and anesthesiologists were asked to complete a preeducation questionnaire to assess baseline knowledge of current and alternative forms of
sedation in the pediatric population. Educational courses were then provided through digital
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platforms. Once completed, a post-education questionnaire was used to analyze and evaluate
effectiveness of teachings.
Protection of Human Subjects
All healthcare personnel mentioned above that are involved in providing care to the
pediatric population were asked to participate in the study. Participants were asked to join the
study via email and had the ability to withdraw from the study at any time for any reason.
Participants were asked to participate in a pre-educational survey used to collect data on current
knowledge of practice as well as barriers to implementation of evidence-based practice. No
personal or identifiable information was collected from participants. However, information
regarding the participants’ role in the care of the pediatric population was collected. Once
obtained, all data was stored in a protected online database.
Data Collection
Participants of the study were asked to provide general demographic data including, but
not limited to, age, gender, ethnicity, race, education level, and occupation. Additional
information regarding their experience in the health care field including years of experience was
collected. Participants of the study were asked to describe and evaluate the effectiveness of
current practice methods.
Data Management and Analysis Plan
An electronic database was utilized to store and collect information regarding the study.
Pre- and post-educational survey information was collected and analyzed to gather information
regarding the knowledge and barriers to current and possible future practice. Means of the total
scores pre- and post-educational interventions were compared.
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VI. Results
Participants’ Demographics
For this study, a total of 6 anesthesia providers from a large level one trauma center
completed the survey. Informed consent was collected followed by the pretest survey, the
educational PowerPoint module, and a posttest survey. Most participants were female (n = 5,
83.3%) with the remaining participant identifying as male (n = 1, 16,7%). The participants
ranged in ethnicity from African American (n = 2, 33.3%) and Asian (n = 1, 16.7%) to Hispanic
(n = 1, 16.7%) and Other (n = 2, 33.3%). All participants held advanced degrees with the
majority of having completed a Doctoral in Nursing Practice (DNP) degree (n = 5, 83.3%) and
the remaining participant holding a Master’s in Science in Nursing (MSN) degree (n = 1,
16,7%). The participants were surveyed on number of years they have been practicing as
anesthesia providers. Two thirds of the participants were new providers (less than a year, n = 2,
33.3%), while the remain were seasoned professionals having been in practice for more than 10
years (n = 4, 66.6%).
Table 1. Participants’ Demographics
Participants (n = 6)

Number

%

Male

1

16.7%

Female

5

83.3%

African American

2

33.3%

Asian

1

16.7%

Hispanic

1

16.7%

Other

2

33.3%

Bachelors

0

0.0%

MSN

1

16.7%

Gender

Ethnicity

Level of Education
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5

83.3%

Less than 1 year

2

33.3%

1–5

0

0.0%

6 – 10

0

0.0%

More than 10 years

4

66.7%

DNP
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Years of Experience

Participant Knowledge of Pediatric Anxiety and Treatment
During the pretest, data was collected on the participants’ baseline knowledge on the
effects of pediatric anxiety as well as its current treatment. The results of these responses are in
Table 2. In the pediatric population, high levels of preoperative anxiety can lead to several side
effects including tachycardia and higher requirements for anesthetic management. Many
participants recognized that increased need for anesthetic requirements prior to the educational
module (n = 4, 66.7%); however, only 33.3% (n = 2) answered tachycardia as a side effect of
anxiety. A number of participants also stated nausea (n = 2, 33.3%) and hypotension (n = 1,
16.7) as possible side effects. Post-educational knowledge showed a 17% increase in awareness
of tachycardia as a side effect of anxiety. All participants recognized that midazolam (n = 6,
100%) is the most common pharmacological agent being utilized to treat peri-operative anxiety
in the pediatric population. Although initially correct, one participant chose Ketamine as the
agent of choice in the post-test survey. Participants were divided when identifying unwanted
side effects of midazolam, with answers tallying as follows: Postoperative behavioral changes (n
= 2, 33.3%), hypotension (n = 2, 33.3%), respiratory changes (n = 3, 50.0%), and polyuria (n =
1, 16.7%). Post-educational module teaching reveals an increase in knowledge for correct side
effects including postoperative behavioral changes (n = 3, 50.0%), and respiratory changes (n =
5, 83.3%).
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Table 2. Knowledge of Pediatric Anxiety and Treatment
Pre-Test

Post-Test

% change

Nausea

33.3%

50.0%

17%

Hypotension

16.7%

0%

-17%

66.7%

50.0%

-17%

33.3%

50.0%

17%

0%

100%

100%

100%

83.3%

-17%

Dexmedetomidine

0%

0%

0%

Clonidine

0%

0%

0%

33.3%

50.0%

17%

33.3%

16.7%

-17%

50.0%

83.3%

33%

16.7%

0%

-17%

*denotes correct answer

In the pediatric population,
high levels of preoperative
anxiety can lead to: (Select
two)

Higher requirements
for anesthetic
medications*
Tachycardia*
The most common
pharmacological agent being
utilized in the pediatric
population for the use of
peri-operative anxiety is:
Ketamine
Midazolam*

Identify the unwanted side
effects of midazolam. (Select
two)
Postoperative
behavioral changes*
Hypotension
Respiratory
depression*
Polyuria

Participant Knowledge of Dexmedetomidine
In addition to attaining a baseline guide of participants’ knowledge of pediatric anxiety
repercussions and its treatment, the survey also looked at participants’ understanding and
familiarity of DEX. DEX’s clinical effects can be attributed to selective alpha 2 receptor
agonism. Most participants were familiar with this mechanism of action (n = 4, 66.7%),
however, a small majority chose N-Methyl-D-aspartate receptor antagonist (n = 2, 33.3%). Postsurvey results indicate no additional teaching on this subject as overall percentages remained the
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same. DEX has a number of beneficial properties that participants were aware of including its
antianxielytic (n = 3, 50.0%) and pain relief (n = 4, 66.7%) properties. A small percentage of
participants mistakenly chose antipyretic (n = 2, 33.3%) as a possible benefit of DEX; however,
posttest survey results indicated appropriate elimination of knowledge gaps with no participants
choosing this property. In addition, there was an 33% increase in knowledge of DEX’s pain
relief benefits. The peak effects of DEX are established within 15 mins, which only 33% of
participants understood before the educational module. While there was an increase in
awareness of DEX’s duration of peak effects from 33% to 50%, half of the participants
continued to believe that DEX’s peak effect was less than 10 minutes (5 minutes – n = 2, 33%;
7-8 minutes – n = 1, 16.7%).
Table 3. Knowledge of Dexmedetomidine
Pre-Test

Post-Test

% change

0%

0%

0%

33.3%

33.3%

0%

66.7%

66.7%

0%

0%

0%

0%

Antianxiety*

50%

50.0%

0%

Pain relief*

66.7%

100%

33%

Antipyretic

33.3%

0%

-33%

Antiemetic

0%

0%

0%

50.0%

33.3%

-17%

*denotes correct answer

Dexmedetomidine’s clinical
effect can be attributed to
what mechanism of action?
Potent μ-receptor
agonist
N-Methyl-D-aspartate
receptor antagonist
Selective alpha 2
receptor agonist*
Inhibition of alpha 2
delta subunit of
voltage gated calcium
channels
Select the beneficial
properties of
dexmedetomidine. (Select
two)

Select the peak effect of
dexmedetomidine.
5 minutes
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7-8 minutes

16.7%

16.7%

0%

15 minutes*

33.3%

50.0%

17%

30 minutes

0%

0%

0%
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Participant Likelihood of Use of Intranasal Dexmedetomidine in Future Practice
Prior to the educational module, participants were questioned on the likelihood of use of
intranasal DEX for the pediatric population during their clinical practice. A total of 2
participants answered they were “highly likely,” 1 participant answered “neither likely nor
unlikely,” and 3 participants answered “not at all likely” to use DEX. Survey results following
the educational module showed a slight increase in likelihood of use. Half the participants were
either “highly likely” or “likely” to use DEX in their practice. One participant continued to
answer “neither likely nor unlikely” to use DEX, while 2 participants were “not at all likely” to
use DEX in their practice.
Figure 3. Likelihood of Use of Intranasal Dexmedetomidine
How likely are you to utilize intranasal dexmedetomidine
for the pediatric population in your clinical practice?
60%
50%
40%
30%
20%
10%
0%
Highly likely

Likely
Pre-Test

Neither likely nor
unlikely
Post-Test

Not at all likely
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VII. Discussion
Limitations
There were a few limitations to this study with the most relevant being the small sample
size. The study took place at a large health care facility with initial surveys being sent to over
50 participants. A larger response rate would have been ideal, as it would have strengthened
the results of the project. Another factor that was limited for this project was its time
restrictions. The survey itself was available for a total of 3 weeks, which could have limited
the number of participants that had the time to respond. Lastly, the survey was limited to an
online format. Online platforms are unpersonal, often times not engaging, and are limited in
two-way participation. These qualities could have possibly discouraged potential participants.
Future Implications of Advance Nursing Practice
In the health care arena, evidence-based practice is imperative to the growth and safety of
the patient and can result in greater overall satisfaction for both the patient and the clinician.26
The main agenda for this intervention was to inform and educate anesthesia providers on
alternative sedation medications that can be utilized in the pediatric population. Adequate
patient sedation with decreased side effects can lead to better outcomes for the patient, greater
satisfaction for parents, and greater fulfillment for anesthesia providers.
Conclusions
The literature review outlined above showcased the many benefits of using intranasal
DEX to help mitigate anxiety and reduce the prevalence of parental separation among the
pediatric population. DEX is not only effective in providing adequate sedation levels but also
comes with the added benefit of minimal respiratory and postoperative behavioral side effects
over midazolam. Additionally, the Quality Improvement Project was designed to inform and
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educate anesthesia providers on the medication profile of DEX. Anesthesia providers
enhanced their knowledge of the potential harm of increased levels of anxiety, side effects of
current medications being utilized to mitigate anxiety, and the uses and benefits of DEX.
Following the education module, anesthesia providers were more likely to incorporate
intranasal DEX into their clinical practice.
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Appendix D. Informed Consent

CONSENT TO PARTICIPATE IN A QUALITY IMPROVEMENT PROJECT

The Use of Intranasal Dexmedetomidine Compared to Oral Midazolam in the Pediatric
Preoperative Population for Separation Anxiety. An Educational Module
SUMMARY INFORMATION
Things you should know about this study:





Purpose: Educational module to improve knowledge in utilizing intranasal dexmedetomidine for
preoperative anxiety in the pediatric population.
Procedures: If you choose to participate, you will be asked to complete a pretest watch a voice
PowerPoint and then a post test
Duration: This will take about a total of 20 minutes total.
Risks: The main risk or discomfort from this research is minimal. There will be minimal risks
involved with this project, as would be expected in any type of educational intervention, which
may have included mild emotional stress or mild physical discomfort from sitting on a chair for
an extended period of time, for instance.





Benefits: The main benefit to you from this research is increase the participants knowledge in
utilizing intranasal dexmedetomidine for preoperative anxiety in the pediatric population.
Alternatives: There are no known alternatives available to you other than not taking part in this
study.
Participation: Taking part in this research project is voluntary. Please carefully read the entire
document before agreeing to participate.

PURPOSE OF THE PROJECT
You are being asked to be in a quality improvement project. The goal of this project is to
improve health care provider knowledge on the use of intranasal dexmedetomidine for
preoperative anxiety in the pediatric population. If you decide to be in this study, you will be one
of approximately 10 people in this research study.
NUMBER OF STUDY PARTICIPANTS
If you decide to be in this study, you will be one of approximately 10 people in this research
study under the purpose of the project.
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DURATION OF THE PROJECT
Your participation will require about 20 minutes of your time. Page 1 of 2
PROCEDURES
If you agree to be in the project, we will ask you to do the following things:
1. Complete an online 10 question pre-test survey via Qualtrics, an Online survey product for which the
URL link is provided
2. Review the educational PowerPoint Module lasting 10 minutes via Qualtrics, an Online survey product
for which the URL link is provided.
3. Complete the online 10 question post-test survey via Qualtrics, an Online survey product for which the
URL link is provided.

RISKS AND/OR DISCOMFORTS
The main risk or discomfort from this research is minimal. There will be minimal risks involved
with this project, as would be expected in any type of educational intervention, which may have
included mild emotional stress or mild physical discomfort from sitting on a chair for an
extended period of time, for instance.
BENEFITS
The following benefits may be associated with your participation in this project: An increased
understanding on the perioperative use of intranasal dexmedetomidine for pre- operative anxiety
in the pediatric population.
The overall objective of the program is to increase the quality of healthcare delivery and improve
healthcare outcomes for our patients.
ALTERNATIVES
There are no known alternatives available to you other than not taking part in this project.
However, if you would like to receive the educational material given to the participants in this
project, it will be provided to you at no cost.
CONFIDENTIALITY
The records of this project will be kept private and will be protected to the fullest extent provided
by law. If, in any sort of report, we might publish, we will not include any information that will
make it possible to identify you as a participant. Records will be stored securely, and only the
project team will have access to the records.

PARTICIPATION: Taking part in this research project is voluntary.
COMPENSATION & COSTS
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There is no cost or payment to you for receiving the health education and/or for participating in
this project.
RIGHT TO DECLINE OR WITHDRAW
Your participation in this project is voluntary. You are free to participate in the project or
withdraw your consent at any time during the project. Your withdrawal or lack of participation
will not affect any benefits to which you are otherwise entitled. The investigator reserves the
right to remove you without your consent at such time that they feel it is in the best interest.
RESEARCHER CONTACT INFORMATION
If you have any questions about the purpose, procedures, or any other issues relating to this
research project, you may contact Shilpa Heald at 734-717-5481 or spate109@fiu.edu and
Yasmine Campbell at ycampbel@fiu.edu.
IRB CONTACT INFORMATION
If you would like to talk with someone about your rights pertaining to being a subject in this
project or about ethical issues with this project, you may contact the FIU Office of Research
Integrity by phone at 305-348-2494 or by email at ori@fiu.edu.
PARTICIPANT AGREEMENT
I have read the information in this consent form and agree to participate in this study. I have had
a chance to ask any questions I have about this study, and they have been answered for me. By
clicking on the “consent to participate” button below I am providing my informed consent.
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Appendix E. Data Collection Instrument

Pretest and Posttest Questionnaire:
The Use of Intranasal Dexmedetomidine Compared to Oral Midazolam in the Pediatric Preoperative Population
for Separation Anxiety. An Educational Module

INTRODUCTION
The primary aim of this QI project is to improve the knowledge of CRNAs pertaining to the utilization of intranasal
dexmedetomidine for preoperative anxiety in the pediatric population.
Please answer the question below to the best of your ability. The questions include demographic information and
knowledge of intranasal dexmedatomidine utilization in pediatric procedural patients. Questions are either in multiple
choice or likert style format and are meant to measure the CRNAs knowledge of the effectiveness of intraoperative
methadone reducing postoperative opioid consumption.
PERSONAL INFORMATION

1.

Gender:
a. Male
b. Female
c. Non-binary
d. Prefer not to answer

2.

Ethnicity:
a. American Indian or Alaska Native
b. Bla
c. Black or African American
d. Hispanic or Latino
e. Native Hawaiian or Other Pacific Islander
f. White
g. Other

3.

Level of Education:
a. Certificate
b. Bachelors
c. Masters
d. Doctoral (DNP, DNAP, EdD, PhD)

4.

Years of experience:
a. Less than 1 year
b. 1 to 5
c. 6 to 10
d. More than 10 years

QUESSIONAIRE
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5.

In the pediatric population, high levels of preoperative anxiety can lead to:
a. Nausea
b. Hypotension
c. Higher requirements for anesthetic medications
d. Tachycardia

6.

The most common pharmacological agent being utilized in the pediatric population for the use of
peri-operative anxiety is:
a. Ketamine
b. Midazolam
c. Dexmedetomidine
d. Clonidine

7.

Identify the unwanted side effects of midazolam. (Select two)
a. Postoperative behavioral changes
b. Hypotension
c. Respiratory depression
d. Polyuria

8.

Dexmedetomidine’s clinical effect can be attributed to what mechanism of action?
a. Potent μ-receptor agonist
b. N-Methyl-D-aspartate receptor antagonist
c. Selective alpha 2 receptor agonist
d. Inhibition of alpha 2 delta subunit of voltage gated calcium channels

9.

Select the beneficial properties of dexmedetomidine. (Select two)
a. Antianxiety
b. Pain relief
c. Antipyretic
d. Antiemetic
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10. Select the peak effect of dexmedetomidine.
a. 5 minutes
b. 7-8 minutes
c. 15 minutes
d. 30 minutes
11. How likely are you to utilize intranasal dexmedetomidine for the pediatric population in your clinical
practice?
a. Highly likely
b. Likely
c. Somewhat likely
d. Not at all likely
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Appendix F. Educational Module

52

DEXMEDETOMIDINE COMPARED TO MIDAZOLAM FOR SEPERATION ANXIETY

Appendix G. Poster
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Appendix H. Dissemination PowerPoint
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